These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

914 related items for PubMed ID: 17950658

  • 1. Late stage antibacterial drugs in the clinical pipeline.
    Projan SJ, Bradford PA.
    Curr Opin Microbiol; 2007 Oct; 10(5):441-6. PubMed ID: 17950658
    [Abstract] [Full Text] [Related]

  • 2. Whither antibacterial drug discovery?
    Projan SJ.
    Drug Discov Today; 2008 Apr; 13(7-8):279-80. PubMed ID: 18405838
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Fighting infections due to multidrug-resistant Gram-positive pathogens.
    Cornaglia G.
    Clin Microbiol Infect; 2009 Mar; 15(3):209-11. PubMed ID: 19335367
    [Abstract] [Full Text] [Related]

  • 6. Unmet medical needs in antibacterial therapy.
    Rice LB.
    Biochem Pharmacol; 2006 Mar 30; 71(7):991-5. PubMed ID: 16280121
    [Abstract] [Full Text] [Related]

  • 7. Update on the antibacterial resistance crisis.
    Croft AC, D'Antoni AV, Terzulli SL.
    Med Sci Monit; 2007 Jun 30; 13(6):RA103-18. PubMed ID: 17534243
    [Abstract] [Full Text] [Related]

  • 8. What's new on the antimicrobial horizon?
    Song JH.
    Int J Antimicrob Agents; 2008 Dec 30; 32 Suppl 4():S207-13. PubMed ID: 19134521
    [Abstract] [Full Text] [Related]

  • 9. Future antibiotics scenarios: is the tide starting to turn?
    Theuretzbacher U.
    Int J Antimicrob Agents; 2009 Jul 30; 34(1):15-20. PubMed ID: 19342202
    [Abstract] [Full Text] [Related]

  • 10. Bacterial targets to antimicrobial leads and development candidates.
    Rogers BL.
    Curr Opin Drug Discov Devel; 2004 Mar 30; 7(2):211-22. PubMed ID: 15603255
    [Abstract] [Full Text] [Related]

  • 11. Antibacterial drug discovery in the 21st century.
    Bush K.
    Clin Microbiol Infect; 2004 Nov 30; 10 Suppl 4():10-7. PubMed ID: 15522035
    [Abstract] [Full Text] [Related]

  • 12. Combination drugs, an emerging option for antibacterial therapy.
    Cottarel G, Wierzbowski J.
    Trends Biotechnol; 2007 Dec 30; 25(12):547-55. PubMed ID: 17997179
    [Abstract] [Full Text] [Related]

  • 13. The antimicrobial armamentarium: evaluating current and future treatment options.
    Bosso JA.
    Pharmacotherapy; 2005 Oct 30; 25(10 Pt 2):55S-62S. PubMed ID: 16178676
    [Abstract] [Full Text] [Related]

  • 14. Taking inventory: antibacterial agents currently at or beyond phase 1.
    Bush K, Macielag M, Weidner-Wells M.
    Curr Opin Microbiol; 2004 Oct 30; 7(5):466-76. PubMed ID: 15451501
    [Abstract] [Full Text] [Related]

  • 15. Mechanisms of bacterial resistance to antimicrobial agents.
    Stratton CW.
    J Med Liban; 2000 Oct 30; 48(4):186-98. PubMed ID: 11214188
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Trends in antimicrobial drug development: implications for the future.
    Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE.
    Clin Infect Dis; 2004 May 01; 38(9):1279-86. PubMed ID: 15127341
    [Abstract] [Full Text] [Related]

  • 18. Antimicrobial drug resistance in Taiwan.
    Huang YT, Hsueh PR.
    Int J Antimicrob Agents; 2008 Nov 01; 32 Suppl 3():S174-8. PubMed ID: 19013350
    [Abstract] [Full Text] [Related]

  • 19. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens.
    Cornaglia G, Rossolini GM.
    Clin Microbiol Infect; 2009 Mar 01; 15(3):218-23. PubMed ID: 19335369
    [Abstract] [Full Text] [Related]

  • 20. Prospects and challenges of developing new agents for tough Gram-negatives.
    Meyer AL.
    Curr Opin Pharmacol; 2005 Oct 01; 5(5):490-4. PubMed ID: 16084769
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.